Metropolis Healthcare Ltd. (METROPOLIS) fundamentals
Metropolis Healthcare Ltd. is a listed company in Healthcare Services, part of the Healthcare sector, listed on the NSE as METROPOLIS (ISIN INE112L01020). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Metropolis Healthcare Ltd. does
Metropolis Healthcare Limited is engaged in providing diagnostic services to patients, healthcare providers, and corporates across India and Africa. The Company has a single operating segment, namely Pathology services. It is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, other pathological and radiological investigations. It serves a diverse customer base, including B2C, B2B, and institutional clients. It offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. Its footprint spans 28 states, seven Union Territories, and over 750 towns in India, supported by a robust network of more than 220 laboratories, 4,450+ service centers, and over 10,000 touchpoints.
Valuation and market data
| Last close | ₹534.95 |
|---|---|
| Market capitalisation | ₹11,129 crore |
| Enterprise value | ₹11,353 crore |
| P/E (TTM) | 58.21 |
| Price to book | 7.30 |
| Price to sales (TTM) | 3.78 |
| Book value per share | ₹73.29 |
| Dividend yield | 93.47% |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Listed since | Mon Apr 15 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,382 crore | ₹211 crore | ₹157 crore | 7.60 |
| Mar 2025 | ₹1,233 crore | ₹161 crore | ₹124 crore | 6.01 |
| Mar 2024 | ₹1,115 crore | ₹157 crore | ₹116 crore | 22.63 |
| Mar 2023 | ₹1,087 crore | ₹179 crore | ₹139 crore | 27.14 |
| Mar 2022 | ₹1,173 crore | ₹272 crore | ₹200 crore | 39.00 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 47.8% |
|---|---|
| Foreign institutions (FII) | 11.7% |
| Mutual funds | 33.1% |
| Other domestic institutions | 2.4% |
| Retail and others | 5.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.